<DOC>
	<DOCNO>NCT01335009</DOCNO>
	<brief_summary>This global , Phase 2 , open label , dose selection , proof-of-concept study assess progression free survival subject metastatic melanoma . 80+ subject 29 site U.S. , U.K. , Germany Australia randomize one two dose group : 2 mg/kg , 4 mg/kg . Weekly treatment continue disease progression . Subjects must measurable disease CT Scan MRI must complete least one prior round chemotherapy . Subjects assess Efficacy , PK/PD , Overall survival , Safety ( Adverse Events/Adverse Events Interest , Electrocardiograms ( ECG 's ) , clinical lab , physical exams/vital sign , tolerability ) .</brief_summary>
	<brief_title>Efficacy Study Pharmacokinetic ( PK ) /Pharmacodynamic ( PD ) Relationship Monotherapy MORAb-004 Metastatic Melanoma</brief_title>
	<detailed_description>MORAb-004 monoclonal antibody direct endosialin , cell surface glycoprotein , express cell involve tumor vasculature . Studies find endosialin play key role tumor growth neovessel formation numerous cancer type include melanoma . Preclinical pharmacological study show MORAb-004 potentially useful anti-cancer agent . This clinical trial perform determine efficacy MORAb-004 two dose level subject metastatic melanoma , well establish serum pharmacokinetics pharmacodynamics antibody .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm diagnosis metastatic melanoma At least one prior line systemic treatment confirm progression disease Measurable disease , define RECIST , assess within 4 wks prior study entry At least 3 week interval first infusion test article recent prior systemic anticancer therapy ECOG Performance Status 0 1 Evidence active malignancy require treatment within last 5 year ( basal cell squamous cell carcinoma skin ) , active brain metastasis Clinically significant heart disease ( Congestive heart failure NYHA Class 3 4 , angina well controlled medication , myocardial infarction within 6 mo . ) , ECGs demonstrate clinically significant arrhythmias Brain metastasis Known allergic reaction prior monoclonal antibody therapy Previous treatment MORAb004</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>melanoma</keyword>
	<keyword>malignant</keyword>
	<keyword>metastatic</keyword>
</DOC>